FDA Approves Dupixent for Children with CSU Aged 2 to 11
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: Globenewswire
- FDA Approval: Dupixent (dupilumab) has received FDA approval for the treatment of chronic spontaneous urticaria (CSU) in children aged 2 to 11, marking an expansion of its application in pediatric populations and is expected to significantly enhance the quality of life for these children.
- Clinical Trial Support: The approval is primarily based on data from the LIBERTY-CUPID clinical trial program, demonstrating Dupixent's efficacy in reducing itch severity and urticaria activity, further solidifying its potential in treating chronic diseases driven by type 2 inflammation.
- Market Impact: As the first biologic approved for children over 2 years in the U.S., Dupixent is set to transform the treatment paradigm for CSU, addressing the unmet medical needs of over 14,000 children and enhancing the company's competitiveness in the pediatric pharmaceutical market.
- Global Recognition: In addition to the U.S., Dupixent has been approved for CSU in children aged 2 to 11 in the EU and other countries, showcasing its broad applicability and recognition in the global market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SAN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SAN
Wall Street analysts forecast SAN stock price to fall
2 Analyst Rating
0 Buy
1 Hold
1 Sell
Moderate Sell
Current: 12.330
Low
4.90
Averages
7.40
High
9.91
Current: 12.330
Low
4.90
Averages
7.40
High
9.91
About SAN
Banco Santander SA is a Spain-based company primarily engaged in retail and commercial banking. The Company operates through a model focused on personal and business banking, with significant operations in Europe, Latin America, and the United States. Its strategy emphasizes sustainable growth supported by customer centric operations, digital transformation, capital discipline, and a risk management framework. The Company leads an international network of subsidiaries offering the following services: retail banking, commercial banking, corporate and investment banking, wealth management, insurance, digital payments, capital markets services, advisory, risk‑management solutions, and structured finance.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
FDA Approves Dupixent for Children with CSU Aged 2 to 11
- FDA Approval: Dupixent (dupilumab) has received FDA approval for the treatment of chronic spontaneous urticaria (CSU) in children aged 2 to 11, marking an expansion of its application in pediatric populations and is expected to significantly enhance the quality of life for these children.
- Clinical Trial Support: The approval is primarily based on data from the LIBERTY-CUPID clinical trial program, demonstrating Dupixent's efficacy in reducing itch severity and urticaria activity, further solidifying its potential in treating chronic diseases driven by type 2 inflammation.
- Market Impact: As the first biologic approved for children over 2 years in the U.S., Dupixent is set to transform the treatment paradigm for CSU, addressing the unmet medical needs of over 14,000 children and enhancing the company's competitiveness in the pediatric pharmaceutical market.
- Global Recognition: In addition to the U.S., Dupixent has been approved for CSU in children aged 2 to 11 in the EU and other countries, showcasing its broad applicability and recognition in the global market.
See More
Americans Prioritize Savings as Top Financial Goal for 2026
- Increased Savings Intent: 76% of American consumers indicate that saving more is their top financial goal for 2026, reflecting a strong focus on future financial health, particularly driven by anticipated tax refunds.
- Tax Refund Savings Plans: Among those expecting a tax refund, 88% plan to save at least a portion of it, demonstrating a proactive attitude towards utilizing additional funds for savings, which could enhance overall savings growth.
- Potential of High-Yield Accounts: The survey reveals that 58% of consumers intend to deposit their tax refunds into low-yield accounts, missing the opportunity to earn nearly ten times more interest through high-yield savings accounts or CDs, indicating a lack of awareness about these options.
- Significant Interest Earnings Difference: For the typical saver, contributing an average tax refund to a high-yield account could generate over $1,500 in interest over three years, compared to about $165 from a traditional account, underscoring the importance of selecting the right savings tools.
See More
Financial Stocks Rise as NYSE Financial Index Gains 0.6%
- Market Recovery: Financial stocks showed strong performance on Wednesday afternoon, with the NYSE Financial Index rising 0.6%, indicating a gradual restoration of investor confidence in the financial sector, potentially signaling signs of economic recovery.
- Improved Investor Sentiment: The rise in financial stocks suggests a more optimistic market outlook regarding future interest rate policies, especially as economic data improves, which may attract more capital into the financial sector.
- Positive Industry Outlook: With the stabilization of financial markets, investors are optimistic about the profitability of banks and financial services companies, expecting stronger financial performance in the coming quarters.
- Technical Support: The increase in financial stocks was accompanied by a rise in trading volume, indicating growing interest among market participants in the sector, potentially laying the groundwork for further gains ahead.
See More
SANTANDER SHAREHOLDERS GREENLIGHT ALL MEASURES, INCLUDING CAPITAL RAISE TO FINANCE ACQUISITION OF U.S. LENDER WEBSTER
- Shareholder Approval: Shareholders have approved all proposals presented, including a capital increase.
- Acquisition Funding: The capital increase is intended to help fund the acquisition of U.S. lender Webster.
See More
Seabridge Gold Files 2025 Annual Financial Statements
- Financial Overview: Seabridge Gold reported a net loss of $53.2 million ($0.53 per share) for 2025, a significant increase from a $31.2 million loss ($0.35 per share) in 2024, indicating challenges in cost control and profitability.
- Investment Growth: The company invested $137 million in mineral interests, property, and equipment in 2025, a 25.7% increase from $106.3 million in 2024, demonstrating ongoing commitment to future projects despite short-term financial pressures.
- Asset and Liability Status: As of December 31, 2025, Seabridge's net working capital rose to $109.8 million from $44.8 million in 2024, indicating improved liquidity management and providing a stronger foundation for future project financing.
- Strategic Development Plans: The company plans to spin out 100% of the Courageous Lake project into a new entity, Valor Gold Corp., to advance the project more effectively while focusing on securing partnerships for the KSM project, aiming to enhance shareholder value through strategic restructuring.
See More
M&A Deal Closures Present Opportunities: Target Janus Henderson and Other Stocks.
- Merger and Acquisition Activity: The year has seen significant merger and acquisition activity, with many deals nearing closure.
- Stock Performance: Stocks of companies being acquired are expected to rise upon the completion of these deals.
See More
FDA Approves Dupixent for Children with CSU Aged 2 to 11
- FDA Approval: Dupixent (dupilumab) has received FDA approval for the treatment of chronic spontaneous urticaria (CSU) in children aged 2 to 11, marking an expansion of its application in pediatric populations and is expected to significantly enhance the quality of life for these children.
- Clinical Trial Support: The approval is primarily based on data from the LIBERTY-CUPID clinical trial program, demonstrating Dupixent's efficacy in reducing itch severity and urticaria activity, further solidifying its potential in treating chronic diseases driven by type 2 inflammation.
- Market Impact: As the first biologic approved for children over 2 years in the U.S., Dupixent is set to transform the treatment paradigm for CSU, addressing the unmet medical needs of over 14,000 children and enhancing the company's competitiveness in the pediatric pharmaceutical market.
- Global Recognition: In addition to the U.S., Dupixent has been approved for CSU in children aged 2 to 11 in the EU and other countries, showcasing its broad applicability and recognition in the global market.
See More
Americans Prioritize Savings as Top Financial Goal for 2026
- Increased Savings Intent: 76% of American consumers indicate that saving more is their top financial goal for 2026, reflecting a strong focus on future financial health, particularly driven by anticipated tax refunds.
- Tax Refund Savings Plans: Among those expecting a tax refund, 88% plan to save at least a portion of it, demonstrating a proactive attitude towards utilizing additional funds for savings, which could enhance overall savings growth.
- Potential of High-Yield Accounts: The survey reveals that 58% of consumers intend to deposit their tax refunds into low-yield accounts, missing the opportunity to earn nearly ten times more interest through high-yield savings accounts or CDs, indicating a lack of awareness about these options.
- Significant Interest Earnings Difference: For the typical saver, contributing an average tax refund to a high-yield account could generate over $1,500 in interest over three years, compared to about $165 from a traditional account, underscoring the importance of selecting the right savings tools.
See More
Financial Stocks Rise as NYSE Financial Index Gains 0.6%
- Market Recovery: Financial stocks showed strong performance on Wednesday afternoon, with the NYSE Financial Index rising 0.6%, indicating a gradual restoration of investor confidence in the financial sector, potentially signaling signs of economic recovery.
- Improved Investor Sentiment: The rise in financial stocks suggests a more optimistic market outlook regarding future interest rate policies, especially as economic data improves, which may attract more capital into the financial sector.
- Positive Industry Outlook: With the stabilization of financial markets, investors are optimistic about the profitability of banks and financial services companies, expecting stronger financial performance in the coming quarters.
- Technical Support: The increase in financial stocks was accompanied by a rise in trading volume, indicating growing interest among market participants in the sector, potentially laying the groundwork for further gains ahead.
See More
SANTANDER SHAREHOLDERS GREENLIGHT ALL MEASURES, INCLUDING CAPITAL RAISE TO FINANCE ACQUISITION OF U.S. LENDER WEBSTER
- Shareholder Approval: Shareholders have approved all proposals presented, including a capital increase.
- Acquisition Funding: The capital increase is intended to help fund the acquisition of U.S. lender Webster.
See More
Seabridge Gold Files 2025 Annual Financial Statements
- Financial Overview: Seabridge Gold reported a net loss of $53.2 million ($0.53 per share) for 2025, a significant increase from a $31.2 million loss ($0.35 per share) in 2024, indicating challenges in cost control and profitability.
- Investment Growth: The company invested $137 million in mineral interests, property, and equipment in 2025, a 25.7% increase from $106.3 million in 2024, demonstrating ongoing commitment to future projects despite short-term financial pressures.
- Asset and Liability Status: As of December 31, 2025, Seabridge's net working capital rose to $109.8 million from $44.8 million in 2024, indicating improved liquidity management and providing a stronger foundation for future project financing.
- Strategic Development Plans: The company plans to spin out 100% of the Courageous Lake project into a new entity, Valor Gold Corp., to advance the project more effectively while focusing on securing partnerships for the KSM project, aiming to enhance shareholder value through strategic restructuring.
See More
M&A Deal Closures Present Opportunities: Target Janus Henderson and Other Stocks.
- Merger and Acquisition Activity: The year has seen significant merger and acquisition activity, with many deals nearing closure.
- Stock Performance: Stocks of companies being acquired are expected to rise upon the completion of these deals.
See More
